Allergan given FDA approval of Juvederm for facial wrinkles

New York, June 5 - Allergan, Inc. said the Food and Drug Administration approved its Juvederm gel family of products for correction of facial wrinkles and folds.

Juvederm's proprietary, technologically advanced formulations result in a smooth, natural look and contain the highest concentration of non-animal and cross-linked hyaluronic acid of any dermal filler currently available, the company said. These unique attributes provide optimal results with a single treatment in the majority of patients and deliver sustained results for up to six months or longer.

The FDA approved three different formulations for Juvederm: Juvederm 24HV, a highly cross-linked formulation for more versatility in contouring and volumizing of facial wrinkles and folds; Juvederm 30HV, a more highly cross-linked robust formulation for volumizing and correction of deeper folds and wrinkles; and Juvederm 30, a highly cross-linked formulation for subtle correction of facial wrinkles and folds.

Allergan is a specialty pharmaceutical company located in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.